Chimeric, Mutated, Or Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobulin Fusion Protein, Etc.) Patents (Class 530/387.3)
-
Patent number: 11561229Abstract: Herein is reported a method for the determination of the amount of a bivalent antibody in a serum or plasma sample obtained from a non-human experimental animal, whereby the antibody comprises one or more mutations in the Fc-region compared to the corresponding wild-type Fc-region that has a sequence of SEQ ID NO: 01, 02, or 03, wherein the method comprises the following steps a) immobilizing a non-antibody polypeptide to which more than one copy of the antigen of the antibody is covalently conjugated on a solid surface, b) incubating the immobilized antigen with the sample to form an immobilized antigen-antibody complex, c) incubating the immobilized antigen-antibody complex with the antigen conjugated to a detectable label to form an immobilized ternary complex, and d) determining the amount of the antibody by determining the amount of the detectable label in the immobilized ternary complex.Type: GrantFiled: May 24, 2018Date of Patent: January 24, 2023Assignee: Hoffmann-La Roche Inc.Inventor: Kay-Gunnar Stubenrauch
-
Patent number: 11555071Abstract: The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.Type: GrantFiled: May 31, 2019Date of Patent: January 17, 2023Assignee: LamKap Bio beta Ltd.Inventors: Vanessa Buatois, Stefano Majocchi, Klaus Strein
-
Patent number: 11547099Abstract: The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.Type: GrantFiled: October 22, 2014Date of Patent: January 10, 2023Assignee: Crescendo Biologies LimitedInventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
-
Patent number: 11542340Abstract: Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to specific peptides of C163A or LG3BP, compositions comprising such antibodies and/or fragments, as well as methods of use and devices employing such antibodies and/or fragments.Type: GrantFiled: October 29, 2021Date of Patent: January 3, 2023Assignee: Biodesix, Inc.Inventors: Gary A. Pestano, Hestia Meliert
-
Patent number: 11542308Abstract: The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.Type: GrantFiled: May 23, 2022Date of Patent: January 3, 2023Assignee: Genentech, Inc.Inventors: Yichin Liu, Christine Carine Moussion, Travis William Bainbridge, Iraj Hosseini, Gregory Alan Lazar, Sivan Cohen, Christopher Charles Kemball, Jill M. Schartner
-
Patent number: 11535667Abstract: The applications provides the anti-CD3 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to active CD3+ T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.Type: GrantFiled: June 22, 2018Date of Patent: December 27, 2022Assignees: SYSTIMMUNE, INC., BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.Inventors: Ole Olsen, Phil Tan, Dong Xia, David Jellyman, Brian Kovacevich, Bill Brady, Blair Renshaw, Zeren Gao, Yi Zhu
-
Patent number: 11535674Abstract: The present disclosure discloses a method for expressing and preparing a bivalent bispecific antibody. In the present disclosure, each portion of a bivalent bispecific antibody and an immune hybrid protein thereof is respectively expressed in a suitable prokaryotic or eukaryotic cell system, separated and purified by high-performance affinity chromatography, and then spliced in vitro by trans-splicing reaction mediated by an intein, to prepare the bivalent specific antibody and an immune hybrid protein thereof.Type: GrantFiled: December 16, 2016Date of Patent: December 27, 2022Assignees: SHANGHAI JIAO TONG UNIVERSITY, JECHO LABORATORIES INC., JECHO BIOPHARMACEUTICALS CO LTD.Inventors: Lei Han, Jianwei Zhu, Junsheng Chen, Kai Ding, Yueqing Xie, Hua Jiang, Huili Lu, Baohong Zhang, Lei Zhang
-
Patent number: 11524992Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: GrantFiled: January 24, 2020Date of Patent: December 13, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
-
Patent number: 11512142Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: GrantFiled: May 1, 2020Date of Patent: November 29, 2022Assignees: Merck Sharp & Dohme LLC, Adimab LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
-
Patent number: 11498963Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.Type: GrantFiled: November 8, 2019Date of Patent: November 15, 2022Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Chengcheng Zhang, Mi Deng, Wei Xiong, Zhiqiang An, Ningyan Zhang, Xun Gui, Junke Zheng
-
Patent number: 11498965Abstract: The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.Type: GrantFiled: October 22, 2018Date of Patent: November 15, 2022Assignees: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Ki Su Kim, Jun Hong Jeong, Ae Rin Yoon, Eun Jung Song, Hye Ji Choi, Ok Jae Lim, Yun Jung Lee, Hyung Kwon Lim, Jong Wha Won
-
Patent number: 11492372Abstract: The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations.Type: GrantFiled: December 17, 2021Date of Patent: November 8, 2022Assignee: AMGEN INC.Inventors: Samuel Ray Trejo, Robert Perry Brake
-
Patent number: 11472886Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.Type: GrantFiled: April 2, 2021Date of Patent: October 18, 2022Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Doris Rau, Susanne Mangold, Matthias Klinger, Evelyne Schaller, Susanne Hausmann, Petra Fluhr, Carola Steiger
-
Patent number: 11471518Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.Type: GrantFiled: April 9, 2020Date of Patent: October 18, 2022Assignee: OMNICYTEInventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
-
Patent number: 11459383Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.Type: GrantFiled: March 16, 2017Date of Patent: October 4, 2022Assignee: Tillotts Pharm AGInventors: Tea Gunde, Sebastian Meyer, Esther Maria Furrer
-
Patent number: 11459404Abstract: The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: July 20, 2017Date of Patent: October 4, 2022Assignee: Roche Glycart AGInventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Patent number: 11453719Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.Type: GrantFiled: September 30, 2019Date of Patent: September 27, 2022Assignees: LENTIGEN TECHNOLOGY, INC., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 11447553Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.Type: GrantFiled: November 22, 2016Date of Patent: September 20, 2022Inventors: Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
-
Patent number: 11427628Abstract: The present invention relates to antibody light chain framework regions I to III from V? and framework region IV from V?, with high stability and reduced aggregation propensity.Type: GrantFiled: October 10, 2018Date of Patent: August 30, 2022Assignee: NUMAB THERAPEUTICS AGInventors: Sebastian Meyer, David Urech
-
Patent number: 11427650Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.Type: GrantFiled: January 21, 2019Date of Patent: August 30, 2022Assignee: UCB BIOPHARMA SRLInventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
-
Patent number: 11427633Abstract: Disclosed are an anti-CD19 humanized antibody prepared from a murine monoclonal antibody, a chimeric antigen receptor containing the humanized antibody, and an immune cell expressing the humanized antibody. Not only does the humanized antibody of the present invention not produce an anti-antibody response (AAR) and a human anti-mouse antibody response (HAMA), but same also has better affinity than a murine antibody, and has excellent activity and safety, thereby providing a new means for treating CD19-expressing tumors.Type: GrantFiled: December 13, 2017Date of Patent: August 30, 2022Assignee: CRAGE medical Co., LimitedInventors: Peng Wang, Huiping Gao, Zhimin Shi, Zonghai Li
-
Patent number: 11407823Abstract: Described herein are compositions and methods relating to LAP-binding agents, including, for example, anti-LAP antibodies, and to their use in methods of treatment of cancer. LAP-binding agents affected both systemic and intra-tumor immunity and were shown effective to treat a broad spectrum of cancer types.Type: GrantFiled: March 15, 2019Date of Patent: August 9, 2022Assignee: The Brigham and Women's Hospital, Inc.Inventors: Howard L. Weiner, Galina Gabriely, Andre Pires Da Cunha, Takatoku Oida
-
Patent number: 11401299Abstract: The invention relates to the generation of multispecific antibody mixtures include a subset of antibodies isolated from a mixture of two or more monospecific antibodies and one or more bispecific antibodies, wherein all antibodies in the subset have the same common heavy chain. The invention also relates to methods of isolating, purifying, or otherwise producing such a subset of antibodies by using at least one affinity chromatography step. The invention also relates to methods of using such a subset of antibodies in a variety of therapeutic indications.Type: GrantFiled: July 23, 2018Date of Patent: August 2, 2022Assignee: NovImmune SAInventors: Nicolas Fischer, Giovanni Magistrelli, Krzysztof Masternak
-
Patent number: 11390673Abstract: The present invention is directed to compositions of matter useful for the treatment of cancer in mammals and to methods of using those compositions of matter for the same. Antibodies specific for podocalyxin designated Ab1 and 3G2 are disclosed, as is the use of said antibodies for the inhibition of growth of a tumor that expresses podocalyxin, and the use of said anti bodies for targeting tumour endothelial cells that express podocalyxin.Type: GrantFiled: August 12, 2019Date of Patent: July 19, 2022Inventors: John Stephen Babcook, Kelly Marshall McNagny, Calvin D. Roskelley, Bradley John Hedberg, Kimberly Ashely Snyder, Michael R. Hughes
-
Patent number: 11390680Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: February 14, 2020Date of Patent: July 19, 2022Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
-
Patent number: 11357866Abstract: A composition of matter and method of treating HIV with mesenchymal stem cells (MSC) is disclosed. Specifically, MSCs are transduced with vectors incorporating an anti-viral fusion inhibitor, such as a C46-derived peptide or neutralizing antibody. The transduced MSCs are capable of expression the inhibitor and preventing HIV virus-cell fusion.Type: GrantFiled: June 7, 2018Date of Patent: June 14, 2022Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Stephen E. Braun, Debasis Mondal, Bruce A Bunnell, Narae Lee
-
Patent number: 11351269Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.Type: GrantFiled: June 30, 2016Date of Patent: June 7, 2022Assignee: Seagen Inc.Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
-
Patent number: 11325981Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.Type: GrantFiled: June 18, 2018Date of Patent: May 10, 2022Assignee: Zymeworks Inc.Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
-
Patent number: 11326182Abstract: The invention provides compositions and methods for the preparation, manufacture and therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral genomes encoding one or more antibodies or antibody fragments or antibody like polypeptides, for the prevention and/or treatment of diseases and/or disorders.Type: GrantFiled: April 28, 2017Date of Patent: May 10, 2022Assignee: Voyager Therapeutics, Inc.Inventors: Steven Paul, Donna T. Ward
-
Patent number: 11319379Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, affinity maturated single chain variable fragment (scFv) antibodies that bind TAG-72 on cancer cells are disclosed.Type: GrantFiled: August 4, 2017Date of Patent: May 3, 2022Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventor: Hatem Soliman
-
Patent number: 11319526Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.Type: GrantFiled: May 16, 2019Date of Patent: May 3, 2022Assignee: Seagen Inc.Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
-
Patent number: 11319365Abstract: The present disclosure relates to antibodies that bind selectively to pathological Tau, including compositions and methods relating to such antibodies, such as for treating tauopathies, neurodegenerative diseases associated with pathological aggregation of Tau.Type: GrantFiled: September 10, 2021Date of Patent: May 3, 2022Assignee: APRINOIA THERAPEUTICS LIMITEDInventors: Ming-Kuei Jang, Chin-Yin Tai
-
Patent number: 11312779Abstract: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.Type: GrantFiled: February 28, 2020Date of Patent: April 26, 2022Assignee: ZYMOGENETICS, INC.Inventor: Janine M. Bilsborough
-
Patent number: 11267870Abstract: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.Type: GrantFiled: October 2, 2018Date of Patent: March 8, 2022Assignee: ACADEMIA SINICAInventors: Chi-Huey Wong, Chung-Yi Wu
-
Patent number: 11261238Abstract: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric and in aggregated form to a cation exchange material under conditions whereby the immunoglobulin in monomeric form does not bind to the cation exchange material, and recovering the immunoglobulin in monomeric form from the solution after the contact with the cation exchange material.Type: GrantFiled: February 3, 2020Date of Patent: March 1, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Roberto Falkenstein, Claudia Giessel
-
Patent number: 11261262Abstract: The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an IgG CH1 domain and a second polypeptide where there is at least one mutation in the IgG CH3 domain that abolishes the ability of the second polypeptide to bind CH3-specific affinity media such that the first and second polypeptides have different affinities with respect to CH1 and CH3 specific affinity reagents that allows rapid isolation by differential binding. The invention also provides bispecific antibodies that have CH1 and CH3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding. The invention also concerns bispecific antibodies which are heterodimers of two IgG heavy chains that differ by at least two amino acids that allow for rapid isolation based on a differential affinity of one mutated heavy chain and a second mutated heavy chain toward two different affinity reagents.Type: GrantFiled: September 3, 2014Date of Patent: March 1, 2022Assignee: NovImmune SAInventors: Nicolas Fischer, Giovanni Magistrelli, Francois Rousseau, Krzysztof Masternak, Pauline Malinge
-
Patent number: 11235059Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: GrantFiled: November 6, 2018Date of Patent: February 1, 2022Assignee: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Patent number: 11225528Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: March 14, 2019Date of Patent: January 18, 2022Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 11214791Abstract: A binding agent to a target molecule, or method or kit where the binding agent is selected from a library where each variant has a circular permutation of the FHA domain where the rearrange does not substantially disrupt the FHA domain's beta-sheet scaffold or increase the stability of the beta-sheet scaffold. The randomized regions of the FHA domain include the endogenous binding interface the FHA domain, the region opposite of the endogenous binding interface, and the circular permutation region.Type: GrantFiled: April 25, 2017Date of Patent: January 4, 2022Inventors: Rajika Perera, Michael Longo
-
Patent number: 11214627Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: GrantFiled: June 8, 2017Date of Patent: January 4, 2022Assignee: UCB BIOPHARMA SRLInventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
-
Patent number: 11203643Abstract: Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.Type: GrantFiled: March 19, 2021Date of Patent: December 21, 2021Assignee: LYVGEN BIOPHARMA HOLDINGS LIMITEDInventors: Jieyi Wang, Yi Wu
-
Patent number: 11192953Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.Type: GrantFiled: May 14, 2018Date of Patent: December 7, 2021Assignee: KYOWA KIRIN CO., LTD.Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
-
Patent number: 11186642Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.Type: GrantFiled: February 22, 2017Date of Patent: November 30, 2021Assignees: CITY OF HOPE, THOMAS JEFFERSON UNIVERSITYInventors: John C. Williams, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
-
Patent number: 11168149Abstract: The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.Type: GrantFiled: December 16, 2016Date of Patent: November 9, 2021Assignees: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., SUZHOU ALPHAMAB CO., LTD.Inventor: Ting Xu
-
Patent number: 11168112Abstract: Fusion proteins of C1q peptides and HMBG1 A-box or HMBG1 B-box, or C1q peptides and DWESY peptide are provided, and methods of use thereof.Type: GrantFiled: January 31, 2019Date of Patent: November 9, 2021Assignee: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCHInventor: Betty A. Diamond
-
Patent number: 11135262Abstract: This invention relates to the treatment of cervical tumor caused by human papillomavirus (HPV) infection. In particular, the invention provides methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection using a polynucleotide encoding an E6/E7 fusion protein.Type: GrantFiled: August 14, 2015Date of Patent: October 5, 2021Assignee: GENEXINE, INC.Inventors: Hyun-Tak Jin, Hye Seong Lim, You Suk Suh, Eun Joo Nam
-
Patent number: 11111315Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: April 4, 2018Date of Patent: September 7, 2021Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 11098105Abstract: Provided herein are heteromultimer constructs with reduced or silenced effector function. In an embodiment is provided a heteromultimer construct comprising an IgG Fc construct having a first and a second Fc polypeptide, each Fc polypeptide comprising a modified lower hinge region wherein: the modified lower hinge region of said first Fc polypeptide comprises at least one amino acid modification, the modified lower hinge region of said second Fc polypeptide comprises at least one amino acid modification which is different from at least one amino acid modification of said first Fc polypeptide, and the IgG Fc construct displays reduced binding to all Fc? receptors and to C1q protein as compared to a corresponding parent IgG Fc construct. Also provided are methods of producing such heteromultimer constructs, and methods of reducing ADCC for an antibody construct by reducing effector function.Type: GrantFiled: May 30, 2014Date of Patent: August 24, 2021Assignee: ZYMEWORKS INC.Inventor: Eric Escobar-Cabrera
-
Patent number: 11065341Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.Type: GrantFiled: December 12, 2017Date of Patent: July 20, 2021Assignee: Children's Hospital & Research Center at OaklandInventors: Gregory R. Moe, Charles Paul Plested
-
Patent number: 11065286Abstract: Provided herein are oncolytic vaccinia viruses which have been modified to contain an exogenous nucleic acid that codes for a variant HMGB1 protein. Such vaccinia viruses modified to contain nucleic acid encoding variant HMGB1 and that express a variant HMGB1 or a fragment thereof can achieve a synergistic effect in combination with chemotherapy. Methods of using oncolytic vaccinia viruses modified to contain an exogenous nucleic acid that codes for a variant HMGB1 protein, in the treatment of various cancers, are also provided.Type: GrantFiled: September 21, 2017Date of Patent: July 20, 2021Inventor: Stephen H. Thorne